Faes Farma, S.a. · BME:FAE
Faes Farma — Q1 2026 Earnings Presentation
18 slides from Faes Farma's earnings presentation, Apr 1, 2026
Slide 1: Report Q1 2026 Faes Farma
aft FAES FARMA REPORT Q1 2026 FAES FARMA
Slide 2: Índice
Índice 1/ 2/ 3/ Highlights and key Business Q1 2026 figures performance Results
Slide 3: Highlights and key figures
1/ Highlights and key figures
Slide 4: Highlights Q1 2026
HIGHLIGHTS AND KEY FIGURES Highlights Q1 2026 Total revenue +31% (+10% on a like-for-like basis) , with growth driven mainly by the integration of acquisitions and the strong Business performance of international Markets, in both direct sales and licensing. Pharma revenue +31%, with the integration
Slide 5: Key figures Q1 2026
HIGHLIGHTS AND KEY FIGURES Key figures Q1 2026 Revenue EBIT 200.1 M€ 36.4 M€ 31% 7% EBITDA Net profit 48.2 M€ 30.8 M€ 23% 9% 5
Slide 6: Business performance Q1 2026
2/ Business performance Q1 2026
Slide 7: Revenue by portfolio line
BUSINESS PERFORMANCE Q1 2026 Revenue by portfolio line €M Millions of euros Q1 2026 Q1 2025 % Bilastine Pharma 175.3 134.1 31% Bilastine maintains its leading position with slight increase of +1% this quarter. Its strong performance in Europe and the Asia-Pacific region is particularly Pharma top 3
Slide 8: Revenue by business area
BUSINESS PERFORMANCE Q1 2026 Revenue by business area Millions of euros Q1 2026 Q1 2025 % Pharma 175.3 134.1 31% Animal Nutrition and Health Pharma Iberia 66.5 58.8 13% 11% Pharma Iberia 34% Pharma International (without licenses) 68.5 35.8 92% Pharma Licenses Pharma Licensing 40.2 39.5 2% 20% Anima
Slide 9: Pharma Iberia
BUSINESS PERFORMANCE Q1 2026 Pharma Iberia Revenue Q1 2026 SPAIN -1% 66.5 M€ 13% Prescription remained stable during the quarter. Following a more subdued start to the year, performance in March was España Portugal clearly positive, driven mainly by growth in calcifediol +7%. 49.8 49.4 Healthcare y
Slide 10: Pharma International
BUSINESS PERFORMANCE Q1 2026 Pharma International Revenue Q1 2026 LATAM 23% 68.5 M€ 92% Latin America is establishing as the company’s main area of organic growth. Most markets are recording significant growth — Colombia (+30 %), Ecuador (+20 %), Peru (+20 %), Mexico (+25 %) and Central America (+18
Slide 11: Pharma Licensing
BUSINESS PERFORMANCE Q1 2026 Pharma Licensing Revenue Q1 2026 BILASTINE LICENSE 1% 40.2 M€ 2% Bilastine is showing modest growths, driven mainly by the expansion of the orodispersible formulation in Europe and strong performance in the Asia-Pacific region. In Japan, a slowdown in sales is beginning
Slide 12: Farm Faes
BUSINESS PERFORMANCE Q1 2026 Farm Faes Revenue Q1 2026 21.9 M€ 31% FARM Faes 21.9 16.7 A positive start to the year, driven by sales growth, improved efficiencies, and strong operational management. Iberia performed well, and ISF made a significant contribution, Q1 2025 Q1 2026 continuing to be one
Slide 13: Q1 2026 Results
af FAES FARMA Q1 2026
Slide 14: Q1 2026 Income statement
Q1 2026 RESULTS Q1 2026 Income statement Thousand € 2026 2025 % change Net turnover 193,587 145,565 33.0% INCOME Other operating income 6,483 7,434 -12.8% Strong growth driven by acquisitions, but also by the strong Total Income 200,070 152,999 30.8% performance of the group’s businesses. Cost of sa
Slide 15: 2026 guidance and main drivers
2026 guidance and main drivers REVENUES 2026 EBITDA 2026* LEVERAGE 2026 +17% / +19% +28% / +31 % < 2x Ebitda Vs. 627 M€, 2025 vs 118 M€, 2025 Main growth drivers 2026 ∕ Growth in the strategic international areas of LATAM and Gulf offsetting the impact of the loss of exclusivity (LOE) of the bilasti
Slide 16: Q&A
af FAES FARMA ofp ens FAT Q&A
Slide 17: Disclaimer
DISCLAIMER This presentation has been prepared and published by Faes Pharma Group for information purposes only. This presentation does not constitute a prospectus or an offer or recommendation to invest. This presentation does not constitute a commitment to subscribe, an offer of financing or an of
Slide 18: Appendix: Breakdown of revenue
Q1 2026 Q1 2025 Var % Iberia 66.5 58.8 13% Appendix Pharma Spain Prescription 49.4 31.6 49.8 31.7 -1% 0% Breakdown of revenue Bilastine 5.0 5.2 Calcifediol 12.9 12.1 Mesalazine 1.8 1.7 Other 12.0 12.7 Healthcare & Consumer 17.7 18.1 -2% Portugal Pharma 17.2 9.0 90% Faes Farma Portugal 9.4 9.0 4% Lab